FY2025 EPS Estimates for ImageneBio Cut by Leerink Partnrs

ImageneBio, Inc. (NASDAQ:IMA) – Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for shares of ImageneBio in a report issued on Wednesday, November 12th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings per share of ($6.12) for the year, down from their previous estimate of ($5.63). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for ImageneBio’s current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for ImageneBio’s Q4 2025 earnings at ($1.61) EPS, FY2026 earnings at ($5.87) EPS, FY2027 earnings at ($3.82) EPS, FY2028 earnings at ($4.42) EPS and FY2029 earnings at ($5.54) EPS.

ImageneBio (NASDAQ:IMA) last posted its earnings results on Wednesday, November 12th. The company reported ($2.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.47) by ($1.44).

Other equities analysts have also issued research reports about the company. Leerink Partners started coverage on ImageneBio in a research note on Friday, October 24th. They issued an “outperform” rating and a $30.00 price objective for the company. Zacks Research downgraded ImageneBio from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 29th. Weiss Ratings assumed coverage on shares of ImageneBio in a report on Wednesday, October 22nd. They set a “sell (e-)” rating for the company. Wall Street Zen downgraded shares of ImageneBio from a “hold” rating to a “strong sell” rating in a report on Saturday. Finally, Wedbush decreased their price target on shares of ImageneBio from $25.00 to $23.00 and set a “neutral” rating on the stock in a research note on Friday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $26.50.

ImageneBio Trading Down 2.0%

Shares of NASDAQ:IMA opened at $8.16 on Monday. The stock has a 50 day moving average of $8.26 and a 200 day moving average of $12.66. The company has a market cap of $32.72 million, a PE ratio of -1.01 and a beta of 0.42. ImageneBio has a 12-month low of $7.24 and a 12-month high of $23.28.

Institutional Investors Weigh In On ImageneBio

Large investors have recently modified their holdings of the business. BML Capital Management LLC lifted its stake in shares of ImageneBio by 3.5% during the 1st quarter. BML Capital Management LLC now owns 3,710,803 shares of the company’s stock worth $4,750,000 after purchasing an additional 124,937 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of ImageneBio by 350.6% in the 1st quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock valued at $72,000 after buying an additional 43,924 shares in the last quarter. Aldebaran Capital LLC purchased a new position in shares of ImageneBio in the 1st quarter worth approximately $317,000. Goldman Sachs Group Inc. raised its stake in shares of ImageneBio by 62.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock worth $98,000 after acquiring an additional 29,369 shares in the last quarter. Finally, Vanguard Group Inc. purchased a new stake in ImageneBio during the third quarter valued at approximately $1,902,000. Institutional investors own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.